Explore /
Poster
/ Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).

Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).

Authors

Alma Habib

The Ohio State University, Division of Hematology, Columbus, OH

Alma Habib , Rina Welkie , Jacob Butman , Pedro C Silberman , Jose Vicente Forero , Yazeed Sawalha , Beth Christian , Kami J. Maddocks , Narendranath Epperla , Samantha Mary Jaglowski , David Alan Bond , Hannah Kyung Choe , Jonathan Edward Brammer , Adam Kittai , Evandro Bezerra , Timothy Voorhees , Sumithira Vasu , Sarah Allison Wall , Marcos J.G. De Lima , Nathan Denlinger

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7033)

DOI

10.1200/JCO.2024.42.16_suppl.7033

Abstract #

7033

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Annual Meeting

Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).

First Author: Amer Methqal Zeidan

Poster

2022 ASCO Annual Meeting

$Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.$